Key Drivers
- Strong liquidity
- No revenue
- Heavy cash burn
AIAI Summary
TYRA has shifted from a long‑duration R&D story into a catalyst-driven, near‑term binary investment where upcoming Phase‑2 interim readouts (SURF302, BEACH301) should drive valuation over the next 12–24 months—position size should therefore be sized to event risk and conviction in those readouts rather than platform optionality. The company's ~$256M cash runway materially lowers immediate financing risk (reducing forced-dilution probability), but positive readouts are required to justify the current >$2B market cap while failures would likely cause sharp repricing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Heavy cash burn
TYRA has a very strong liquidity and low-leverage balance sheet but no revenue, steep operating losses and heavy cash burn that make its investment case entirely dependent on turning R&D and cash runway into future revenue.
Price Behavior
Key Price Behavior Insights:
- •Short‑term uptrend
- •Higher highs/lows
- •Mean‑reversion risk
TYRA is trading above its last month SMA (~$35.03) after a ~17–18% run from $31.58 to $38.18 last month, facing immediate resistance near $38.2 with clustered support in the mid‑$33s that would limit downside so long as price holds above that band, though the sharp run-up raises mean‑reversion risk.
Rapid climb from $31.58 to $38.18 last month (~17–18% gain) increasing correction risk
Sentiment & News
Key News Insights:
- •Dabogratinib 3x3
- •Mid‑2026 readouts
- •Strong cash runway
Tyra Biosciences posted strong Q4/2025 results, launched a three‑trial dabogratinib strategy with multiple interim readouts through 2026, reported ~$256M cash runway into 2027, and drew pronounced investor interest after a 250% stock surge.
The convergence of clear near‑term readouts, a multi‑year cash runway, and rising investor appetite meaningfully reduces development risk and could sustain share momentum if clinical data are positive
Similar Companies in Healthcare
Other companies in the same sector with AI ratings